Ionis Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
Ionis Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 32.9% en 21.9% per jaar. De winst per aandeel zal naar verwachting groeien met 33.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -145.2% zijn.
Belangrijke informatie
32.9%
Groei van de winst
33.5%
Groei van de winst per aandeel
Biotechs winstgroei | 28.5% |
Inkomstengroei | 21.9% |
Toekomstig rendement op eigen vermogen | -145.2% |
Dekking van analisten | Good |
Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Oct 23There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 957 | -429 | -422 | -274 | 17 |
12/31/2025 | 730 | -553 | -530 | -380 | 24 |
12/31/2024 | 623 | -516 | -414 | -365 | 24 |
9/30/2024 | 803 | -359 | -374 | -352 | N/A |
6/30/2024 | 813 | -366 | -375 | -346 | N/A |
3/31/2024 | 777 | -385 | -345 | -323 | N/A |
12/31/2023 | 788 | -366 | -336 | -308 | N/A |
9/30/2023 | 615 | -409 | -574 | -541 | N/A |
6/30/2023 | 631 | -309 | -493 | -456 | N/A |
3/31/2023 | 576 | -329 | -405 | -377 | N/A |
12/31/2022 | 587 | -270 | -294 | -274 | N/A |
9/30/2022 | 875 | 7 | 110 | 130 | N/A |
6/30/2022 | 849 | -28 | 82 | 98 | N/A |
3/31/2022 | 841 | -4 | 35 | 54 | N/A |
12/31/2021 | 810 | -29 | 13 | 31 | N/A |
9/30/2021 | 661 | -608 | -96 | -75 | N/A |
6/30/2021 | 688 | -550 | -59 | -30 | N/A |
3/31/2021 | 708 | -495 | -45 | -11 | N/A |
12/31/2020 | 729 | -444 | -5 | 36 | N/A |
9/30/2020 | 933 | 94 | 173 | 216 | N/A |
6/30/2020 | 940 | 145 | 165 | 213 | N/A |
3/31/2020 | 959 | 169 | 188 | 230 | N/A |
12/31/2019 | 1,123 | 281 | 309 | 346 | N/A |
9/30/2019 | 821 | 433 | 154 | 183 | N/A |
6/30/2019 | 799 | 402 | 154 | 170 | N/A |
3/31/2019 | 752 | 366 | 679 | 697 | N/A |
12/31/2018 | 600 | 277 | 585 | 603 | N/A |
9/30/2018 | 575 | -41 | 485 | 508 | N/A |
6/30/2018 | 548 | -38 | N/A | 563 | N/A |
3/31/2018 | 543 | 9 | N/A | 65 | N/A |
12/31/2017 | 514 | 19 | N/A | 174 | N/A |
9/30/2017 | 507 | 42 | N/A | 127 | N/A |
6/30/2017 | 499 | 52 | N/A | 122 | N/A |
3/31/2017 | 426 | -15 | N/A | 86 | N/A |
12/31/2016 | 373 | -60 | N/A | -112 | N/A |
9/30/2016 | 238 | -184 | N/A | -123 | N/A |
6/30/2016 | 176 | -227 | N/A | -111 | N/A |
3/31/2016 | 258 | -134 | N/A | -12 | N/A |
12/31/2015 | 284 | -88 | N/A | 21 | N/A |
9/30/2015 | 317 | 14 | N/A | 129 | N/A |
6/30/2015 | 312 | 23 | N/A | 95 | N/A |
3/31/2015 | 249 | -24 | N/A | -4 | N/A |
12/31/2014 | 214 | -39 | N/A | 6 | N/A |
9/30/2014 | 172 | -94 | N/A | -79 | N/A |
6/30/2014 | 151 | -92 | N/A | -15 | N/A |
3/31/2014 | 132 | -90 | N/A | 42 | N/A |
12/31/2013 | 147 | -61 | N/A | 63 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat IONS de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat IONS de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat IONS de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van IONS ( 21.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van IONS ( 21.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat IONS binnen 3 jaar verliesgevend zal zijn.